Phase I study of liposomal annamycin

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 427-432

  Booser, Daniel J ^a   Perez Soler, Roman ^a   Cossum, Paul ^a   Esparza Guerra, Laura ^a   Wu, Qing Ping ^a   Zou, Yiyu ^a   Priebe, Waldemar ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracycline; Pharmacokinetics; Phase I study

Indexed keywords

ANNAMYCIN; DOXORUBICIN; LIPOSOME;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; LUNG CARCINOMA; MALE; MELANOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; THROMBOCYTOPENIA; VOMITING;

EID: 0033729436     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000177     Document Type: Article

References (13)

1. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer
2. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
3. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach
4. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes
5. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells
6. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells
7. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells
8. The novel anthracycline annamycin is not affected by p-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
9. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles
10. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity
11. Metabolism of 4'-modified analogs of doxorubicin. Unique glucuronidation pathway for 4'-epidoxorubicin
12. Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography
13. Cardiac complications